Press releases
- Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test - moving forward towards model-development study
- Immunovia announces updated financial calendar
- Immunovia Publishes Full Year Report for 2023
- Invitation to Immunovia's Q4 presentation
- Immunovia appoints Norma Alonzo Palma as new Vice President of Clinical and Medical Affairs
More ▼
Key statistics
On Thursday, Immunovia AB (publ) (0G8X:LSE) closed at 1.40, 42.13% above the 52 week low of 0.985 set on Aug 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 1.40 |
Average volume | -- |
---|---|
Shares outstanding | 45.29m |
Free float | 34.12m |
P/E (TTM) | -- |
Market cap | 80.97m SEK |
EPS (TTM) | -8.27 SEK |
Data delayed at least 20 minutes, as of Mar 21 2024 10:13 BST.
More ▼